Phase 2 INSTANT study results demonstrate rapid restoration of normal heart rhythm with a predictable and favorable safety profile for orally inhaled flecainide. [caption id="attachment_23370" align="aligncenter" width="800"] Meisa Propst, VP of Clinical Operations at InCarda, presented the P2 INSTANT Safety Analysis Poster at the 2022 AF...
Our CEO Grace Colón was recognized by the Biotechnology Innovation Organization in a list of 25 Hispanic Trailblazers to Know in Science and Biotech during #HispanicHeritageMonth2021 #biotech#diversityandinclusion 18. Dr. Grace E. Colón – In her tenure as President and CEO of InCarda Therapuetics, Inc., is in...
Luiz Belardinelli, our Chief Medical Officer will be presenting at the Chief Medical Officer Summit 360˚ on Oct 14, 2021. The presentation will focus on: The Value of Wearable Biosensors in Late-Stage Clinical Development This session focuses on how biosensors enable innovative trial design, novel endpoints and...
Mick Hurrey, VP of Product Development was a speaker at the American Drug Delivery & Formulation Summit 2021 ...
Carlos Schuler, COO & CTO speaking at the 2nd Annual Inhalation and Respiratory Drug Conference on Sept 10, 2021. ...
Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 San Francisco, CA – June 23, 2021 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held...
InCarda CEO Grace Colón was elected to the Board of the Biotechnology Innovation Organization “I’m honored to join the BIO board as part of the Emerging Companies Section Governing Board,” said Grace Colón. “BIO is the undisputed global leader in biotechnology education, collaboration and advocacy, and...
Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in Atrial Fibrillation in Q3 2021; Data Expected 2H 2022 Appointment of Angela Wang as CFO Strengthens...
InCarda CEO Grace Colón was elected to the board of the MIT Corporation (the Institute’s board of trustees), for a five year term, effective July 1, 2021. “I am thrilled and beyond honored to share this news,” said Grace Colón. "As an MIT PhD alum, MIT...
YWIB-San Francisco Bay Area: Spring Into STEM–Extraordinary Leaders Transforming the Future of STEM The San Francisco Bay Area Chapter of Young Women In Bio is thrilled to bring together an extraordinary group of leaders at the forefront of science. Join us for an inspiring discussion with...